miR‑133b is a potential diagnostic biomarker for Alzheimer's disease and has a neuroprotective role

  • Authors:
    • Qin Yang
    • Qiuling Zhao
    • Yanliang Yin
  • View Affiliations

  • Published online on: August 5, 2019     https://doi.org/10.3892/etm.2019.7855
  • Pages: 2711-2718
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNAs (miRNAs/miRs) are involved in post‑transcriptional gene regulation and aberrant expression of miRNAs has been widely detected in various human diseases. The aim of the present study was to examine the serum levels of miR‑133b in patients with Alzheimer's disease (AD), and to explore its diagnostic value and neuroprotective role in AD. Reverse transcription‑quantitative PCR was applied to analyze the serum levels of miR‑133b in 105 AD patients and 98 healthy controls. A cell model of AD was established by treating SH‑SY5Y cells with amyloid β (Aβ)25‑35, and the resulting effect on miR‑133b expression was determined. Cell viability and apoptosis were also measured. A dual‑luciferase assay was used to validate a target gene of miR‑133b. Receiver operating characteristic (ROC) curve analysis was also applied to assess the specificity and sensitivity of miR‑133b to diagnose AD. The results indicated that the serum levels of miR‑133b were significantly downregulated in AD patients and SH‑SY5Y cells treated with Aβ25‑35 (all P<0.001). A positive correlation between the serum levels of miR‑133b and the Mini‑Mental State Examination score of AD patients was determined (r=0.8814, P<0.001). The area under the ROC curve for miR‑133b regarding the diagnosis of AD was 0.907, with a sensitivity of 90.8% and specificity of 74.3% at the cutoff value of 1.70. Overexpression of miR‑133b significantly attenuated the Aβ25‑35‑induced inhibition of cell viability (P<0.01) and induction of cell apoptosis (P<0.01). The luciferase reporter assay demonstrated that epidermal growth factor receptor (EGFR) is a target gene of miR‑133b. In conclusion, miR‑133b may serve as a novel diagnostic biomarker for AD and it may have a neuroprotective role in AD and targets EGFR.

Related Articles

Journal Cover

October 2019
Volume 18 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yang, Q., Zhao, Q., & Yin, Y. (2019). miR‑133b is a potential diagnostic biomarker for Alzheimer's disease and has a neuroprotective role. Experimental and Therapeutic Medicine, 18, 2711-2718. https://doi.org/10.3892/etm.2019.7855
MLA
Yang, Q., Zhao, Q., Yin, Y."miR‑133b is a potential diagnostic biomarker for Alzheimer's disease and has a neuroprotective role". Experimental and Therapeutic Medicine 18.4 (2019): 2711-2718.
Chicago
Yang, Q., Zhao, Q., Yin, Y."miR‑133b is a potential diagnostic biomarker for Alzheimer's disease and has a neuroprotective role". Experimental and Therapeutic Medicine 18, no. 4 (2019): 2711-2718. https://doi.org/10.3892/etm.2019.7855